Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 454 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Amyotrophic Lateral Sclerosis(ALS) Clear all
Terminated Phase 2 Interventional Results available

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

NCT03679975
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Riluzole Oral Soluble film (ROSF) 50 mg
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 14, 2026, 9:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

NCT05137665
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Target ALS Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Georgetown, District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 14, 2026, 9:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrospinal Fluid Repository

NCT00714636
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 14, 2026, 9:16 AM EDT
No Longer Available No phase listed Expanded access

IC14 for ALS Patients Expanded Access

NCT04309604
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
IC14
Biological
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 14, 2026, 9:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ASSESS ALL ALS Study

NCT06578195
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 14, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Virtual Seating Coach on Power Wheelchairs of Persons With Amyotrophic Lateral Sclerosis (ALS)

NCT05742828
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Virtual Seating Coach
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 14, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01786603
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Richard Barohn, MD
Other
Eligibility
21 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 14, 2026, 9:16 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

NCT04856982
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions
Tofersen, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 14, 2026, 9:16 AM EDT
Active, not recruiting No phase listed Observational

Obi Medical Robot: Evaluating Effectiveness Related to Usability

NCT07151950
View directory record Official record
Conditions
Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
Interventions
One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils
Device
Lead sponsor
Desin LLC
Industry
Eligibility
5 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 14, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]

NCT00005674
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Creatine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 9:16 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 14, 2026, 9:16 AM EDT
Not listed No phase listed Observational

Telespirometry in Amyotrophic Lateral Sclerosis (ALS)

NCT05106569
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Spirometry
Diagnostic Test
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Syracuse, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 14, 2026, 9:16 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

NCT05349721
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PTC857, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Orange, California • San Francisco, California • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 14, 2026, 9:16 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS

NCT04749433
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
[11C]CPPC Injection
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 14, 2026, 9:16 AM EDT
Not listed Phase 2 Interventional

Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

NCT01730716
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Human spinal cord stem cell implantation
Device
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 14, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT01938495
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NeuRx® Diaphragm Pacing System™ (DPS)
Device
Lead sponsor
Barrow Neurological Institute
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 14, 2026, 9:16 AM EDT
Completed No phase listed Observational

Speech Analysis in ALS Patients

NCT03868345
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
Interventions
Not listed
Lead sponsor
Barrow Neurological Institute
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 14, 2026, 9:16 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 14, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional

Evaluation of a Structurally Suitable Neck Exoskeleton in Patients With Amyotrophic Lateral Sclerosis

NCT07491562
View directory record Official record
Conditions
ALS - Amyotrophic Lateral Sclerosis
Interventions
powered neck exoskeleton
Device
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 14, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

NCT06266403
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction, Clear Speech Structured Communicative Interaction
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 14, 2026, 9:16 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Digital Speech Markers for Monitoring ALS in Spanish Speakers

NCT07341334
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
Interventions
Not listed
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 14, 2026, 9:16 AM EDT
Terminated Phase 3 Interventional

Continuation Study for Latozinemab

NCT06111014
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Latozinemab
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 14, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

NCT01536249
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Cimetidine plus Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 14, 2026, 9:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis

NCT00023075
View directory record Official record
Conditions
Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 9:16 AM EDT